-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News in the Golden Autumn! Shijiazhuang Sihua Pharmaceutical Group’s Linezolid Sodium Chloride Injection (300 ml) Has Been Approved
Category:
发布时间：2023-10-17
【概要描述】
In the golden autumn season, Shijiazhuang No. 4 Pharmaceutical has reaped a series of breakthroughs in research and development innovation. On October 17, the group’s linezolid sodium chloride injection (300 ml), submitted as a Class 3 chemical drug, received approval for drug production registration from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This follows the group’s earlier receipt, within the past week, of production registration approvals for tinidazole tablets (0.5 g) and ornidazole tablets (0.5 g), marking yet another new product approval.
In the golden autumn season, Shijiazhuang No. 4 Pharmaceutical has reaped a series of breakthroughs in R&D and innovation. On October 17, the company’s linezolid sodium chloride injection (300 ml), submitted as a Class 3 chemical drug, received approval for drug production registration from the National Medical Products Administration, which also deems it to have passed the consistency evaluation. This follows closely on the heels of the company’s earlier receipt, within the past week, of production registration approvals for tinidazole tablets (0.5 g) and ornidazole tablets (0.5 g), marking yet another new product approval for Shijiazhuang No. 4 Pharmaceutical.
According to reports, linezolid sodium chloride injection is indicated for the treatment of infections caused by susceptible strains of specific microorganisms, including hospital-acquired pneumonia, community-acquired pneumonia, complicated skin and soft-tissue infections, and uncomplicated skin and soft-tissue infections.
Previously, the Group obtained marketing approval for Linezolid Glucose Injection (100 mL) in 2021. The recent approval of this new product further enriches the Group’s product pipeline and enhances its market competitiveness. To date, the Group has either obtained or been deemed to have obtained consistency evaluation for a total of 59 drug varieties encompassing 77 dosage forms.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091